Based on CD133’s activation of an AKT/p-BAD survival pathway in trametinib-treated human melanoma stem cells as a mechanism for trametinib resistance, we next targeted the AKT pathway in BAKP and POT cells harboring NRASQ61K and NRASQ61R mutations, respectively. This evidence concerns the gene BAD and melanoma.